A Phase 2 interventional study of KVD824 and Placebo to KVD824 in Angioedema, Hereditary, Types I and II, sponsored by KalVista Pharmaceuticals, Ltd.. Terminated at 33 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
KalVista Pharmaceuticals, Ltd. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of HAE type I or II at any time in the medical history:
During the Run-in Period subject meets one of the following criteria:
Subjects who are fertile and heterosexually active must adhere to requirements throughout the trial as follows:
a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include: i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4).
ii) Intrauterine device (IUD). iii) Intrauterine hormone-releasing system (IUS). iv) Bilateral tubal occlusion. v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of and that the vasectomized partner has received medical assessment of surgical success).
b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner.
Subjects who are not fertile or not sexually active, as defined below, do not require contraception.
Exclusion Criteria
Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit.
Note: These medications include but are not limited to the following:
Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole.
Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort.
Inadequate organ function, including but not limited to;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg KVD824 twice a day for 12 weeks
Drug: KVD824
Two 300 mg KVD824 tablets twice a day for 12 weeks
Drug: KVD824
Three 300 mg KVD824 tablets twice a day for 12 weeks
Drug: KVD824
One, two or three placebo tablets to be taken twice a day for 12 weeks
Drug: Placebo to KVD824
KVD824 300 mg Modified-Release Tablets
Placebo to KVD824 300 mg Modified-Release Tablets
The Rate of Investigator-confirmed HAE Attacks During the Treatment Period
To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Time frame: 12 weeks
Proportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period.
Logistic regression on subjects were measured without investigator-confirmed HAE Attacks (FAS). Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Time frame: 12 weeks
Rate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period.
A summary of negative binomial regression on investigator-confirmed HAE attacks with conventional treatment is presented for the FAS. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Time frame: 12 weeks
Angioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline)
AE-QoL is a quality of life questionnaire with a range of 0 (minimum) to 100 (maximum). A total score of 100 indicates worst possible impairment. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Time frame: 12 weeks
Angioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline).
AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Time frame: 12 weeks
Proportion of Subjects With an AECT Score ≥12 at the End of the Treatment Period.
AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Time frame: 12 weeks
Recruitment Start Date - 06Aug21-27Oct22 First Patient Enrolled - 18Nov21 Long term follow-up planned: No Independent data monitoring committee (IDMC) involvement: No
| Milestone | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| Started | 7 | 8 | 7 | 7 |
| Completed | 5 | 4 | 4 | 2 |
| Not completed | 2 | 4 | 3 | 5 |
| Withdrew: Trial termination by sponsor | 2 | 2 | 1 | 2 |
| Withdrew: Adverse event | 0 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
| HAE attacks | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| The Rate of Investigator-confirmed HAE Attacks During the Treatment Period | 1.476 (0.786 to 2.774) | 1.072 (0.534 to 2.152) | 1.566 (0.814 to 3.012) | 2.380 (1.282 to 4.418) |
Logistic regression on subjects were measured without investigator-confirmed HAE Attacks (FAS). Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
| Participants | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| Proportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period. | 1 | 2 | 3 | 1 |
A summary of negative binomial regression on investigator-confirmed HAE attacks with conventional treatment is presented for the FAS. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
| Est. treated attack rate over 4 weeks | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| Rate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period. | 1.003 (0.461 to 2.183) | 1.093 (0.485 to 2.464) | 1.229 (0.554 to 2.728) | 1.635 (0.754 to 3.548) |
AE-QoL is a quality of life questionnaire with a range of 0 (minimum) to 100 (maximum). A total score of 100 indicates worst possible impairment. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
| Scores on a Scale 0-100 | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| Angioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline) | -5.46 ± 16.281 | -15.69 ± 23.097 | -3.68 ± 16.889 | 0.74 ± 16.398 |
AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
| Scores on a Scale 0-16 | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| Angioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline). | 2.6 ± 4.93 | 5.5 ± 3.83 | 1.3 ± 6.68 | -1.5 ± 3.70 |
AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
| Participants | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| YES | 4 | 5 | 2 | 1 |
| NO | 3 | 1 | 4 | 3 |
| MISSING | 0 | 2 | 1 | 3 |
Collected over Safety analyses were performed by treatment group using the SAF and were presented during treatment. period. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 300 mg KVD824 BID | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| 600 mg KVD824 BID | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| 900 mg KVD824 BID | 0/7 (0%) | 2/7 (28.6%) | 6/7 (85.7%) |
| Placebo to KVD824 BID | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Event | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 0/8 | 1/7 | 0/7 |
| Hepatic steatosisHepatobiliary disorders | 0/7 | 1/8 | 1/7 | 0/7 |
| Hepatitis acuteHepatobiliary disorders | 0/7 | 0/8 | 1/7 | 0/7 |
| Laryngeal oedemaRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/7 |
| Event | 300 mg KVD824 BID | 600 mg KVD824 BID | 900 mg KVD824 BID | Placebo to KVD824 BID |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/7 | 2/8 | 0/7 | 0/7 |
| COVID-19Infections and infestations | 1/7 | 2/8 | 1/7 | 0/7 |
| Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 0/8 | 1/7 | 0/7 |
| AstheniaGeneral disorders | 1/7 | 0/8 | 0/7 | 0/7 |
| Menstruation irregularReproductive system and breast disorders | 0/7 | 0/8 | 1/7 | 0/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/7 |
| Laryngeal oedemaRespiratory, thoracic and mediastinal disorders | 1/7 | 0/8 | 0/7 | 0/7 |
| Mixed anxiety and depressive disorderPsychiatric disorders | 0/7 | 0/8 | 0/7 | 1/7 |
| Alanine aminotransferase increasedInvestigations | 1/7 | 1/8 | 1/7 | 0/7 |
| Aspartate aminotransferase increasedInvestigations | 0/7 | 0/8 | 1/7 | 0/7 |
| Age, Categorical(Participants) | 300 mg KVD824 | 600 mg KVD824 | 900 mg KVD824 | Placebo to KVD824 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 8 | 6 | 7 | 26 |
| >=65 years | 2 | 0 | 1 | 0 | 3 |
| Age, Continuous(years) | 300 mg KVD824 | 600 mg KVD824 | 900 mg KVD824 | Placebo to KVD824 | Total |
|---|---|---|---|---|---|
| Median | 46.0 (25 to 74) | 44.0 (23 to 61) | 35.0 (25 to 66) | 53.0 (26 to 57) | 47.0 (23 to 74) |
| Sex: Female, Male(Participants) | 300 mg KVD824 | 600 mg KVD824 | 900 mg KVD824 | Placebo to KVD824 | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 3 | 3 | 16 |
| Male | 1 | 4 | 4 | 4 | 13 |
| Race (NIH/OMB)(Participants) | 300 mg KVD824 | 600 mg KVD824 | 900 mg KVD824 | Placebo to KVD824 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 0 | 2 |
| White | 6 | 6 | 7 | 5 | 24 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | 300 mg KVD824 | 600 mg KVD824 | 900 mg KVD824 | Placebo to KVD824 | Total |
|---|---|---|---|---|---|
| Puerto Rico | 1 | 0 | 0 | 0 | 1 |
| Hungary | 1 | 1 | 0 | 0 | 2 |
| United States | 1 | 4 | 1 | 2 | 8 |
| Czechia | 0 | 1 | 1 | 0 | 2 |
| United Kingdom | 0 | 0 | 1 | 1 | 2 |
| North Macedonia | 1 | 0 | 0 | 1 | 2 |
| Italy | 1 | 1 | 1 | 2 | 5 |
| Australia | 1 | 0 | 1 | 0 | 2 |
| France | 0 | 1 | 0 | 1 | 2 |
| Bulgaria | 0 | 0 | 1 | 0 | 1 |
| Germany | 1 | 0 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Oct 2022, 11 months.
Results were first posted in May 2026, 3 years 6 months after primary completion. A results delay was requested in Oct 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Feniralstat
Hereditary Angioedema Types I and II
KalVista Pharmaceuticals, Ltd. →